Abstract 2829
Background
TO (CetuGEX) is a second-generation anti-EGFR antibody that specifically binds to EGFR and acts as a competitive antagonist at the ligand binding site. GAT (PankoMab-GEX) is a novel humanized monoclonal antibody, which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1) expressed on tumor cells. Both antibodies are glyco-engineered to potentiate antibody-dependent cellular cytotoxicity (ADCC). Compelling preclinical evidence suggests a complex interaction between EGFR and cell surface expressed TA-MUC1 in driving neoplastic processes and shows a synergistic antibody dependent cell cytotoxicity activity with the dual targeting of these molecules. Based on this evidence, this study aims to assess the tolerability, safety and preliminary activity of a combination with anti-EGFR and anti-TA-MUC1 glyco-engineered antibodies.
Trial design
The GATTO is an open label phase Ib dose evaluation study in patients with EGFR positive metastatic solid tumors, for whom no standard treatment is available. The proposed doses and schedule are 1200 mg Q2W for TO and 1400 mg Q2W for GAT. A staggered approach will be utilized in order to minimize the number of patients exposed and to evaluate the safety of the combination treatment. The first 6 patients will be enrolled into a safety run-in phase where the number of dose-limiting toxicities (DLTs) will be evaluated. Assuming that the safety criteria are met (ie. observation of 0 or 1 DLT), the dose will remain unchanged and further patients will be recruited at the highest dose level. If this is not the case, a step-wise dose reduction approach will be applied. The antitumor activity of the combined treatment will be evaluated as secondary endpoints including best overall response rate (ORR), duration of objective response (DOR), progression-free (PFS) and overall (OS) survival. Extensive pharmacokinetics (PK) and pharmacodynamics (PD) (cellular immune status, serum and tissue biomarkers) will be also analyzed. As of the beginning of May 2018 the study is ongoing and 6 patients are being treated.
Clinical trial identification
NCT03360734.
Legal entity responsible for the study
Glycotope GmbH.
Funding
Glycotope GmbH.
Editorial Acknowledgement
Disclosure
E. Garralda: Investigator: Glycotope GmbH. M. van Hoef: Consultant: Glycotope GmbH. S. Ochsenreither, L. Gianni, D. Lorusso, W. Fiedler, U. Keilholz, K. Klinghammer, C. Dicke, M. Kebenko, I. Matos, J. Tabernero, F. Raspagliesi, G. Del Conte: Investigator: Glycotope GmbH. B. Habel, H. Baumeister, A. Zurlo: Employee: Glycotope GmbH.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract